Home » This Week in NEJM

This Week in NEJM

Jul 21, 2011
Premium

In NEJM this week, researchers in Italy present findings from a study comparing the BEACOPP and ABVD treatment regimens for Hodgkin's lymphoma. BEACOPP is a regimen consisting of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, and has been advocated as the new standard of care for Hodgkin's lymphoma, instead of the ABVD combination which consists of doxorubicin, bleomycin, vinblastine, and dacarbazine, the team writes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

An Expensive Deal

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Figuring Out Who It'll Work For

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

This Week in Nature

In Nature this week: paternal age associated with de novo mutations in children, and more.

Ye Old P-Value

Nature News writes that researchers are still wrangling over the role of the p-value.

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.